← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA8411.3x18.4x25.1x
EV / LTM revenue1751.3x2.6x5.4x
Premium to unaffected price21625%38%60%
Premium to 30-day VWAP4029%42%63%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
020392009: 1 deals, 0 clean on every measure200912010: 28 deals, 4 clean on every measure2010282011: 26 deals, 11 clean on every measure2011262012: 24 deals, 15 clean on every measure2012242013: 22 deals, 13 clean on every measure2013222014: 26 deals, 12 clean on every measure2014262015: 21 deals, 13 clean on every measure2015212016: 16 deals, 11 clean on every measure2016162017: 24 deals, 20 clean on every measure2017242018: 22 deals, 10 clean on every measure2018222019: 19 deals, 6 clean on every measure2019192020: 19 deals, 9 clean on every measure2020192021: 28 deals, 17 clean on every measure2021282022: 31 deals, 21 clean on every measure2022312023: 36 deals, 19 clean on every measure2023362024: 29 deals, 18 clean on every measure2024292025: 39 deals, 24 clean on every measure2025392026: 26 deals, 14 clean on every measure202626
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 18.4x median across 84 dealsHealthcare18.4xn=84Technology: 16.7x median across 170 dealsTechnology16.7xn=170Real Estate: 16.2x median across 51 dealsReal Estate16.2xn=51Business Services: 12.8x median across 74 dealsBusiness Services12.8xn=74Industrials: 12.7x median across 117 dealsIndustrials12.7xn=117Financials: 12.7x median across 25 dealsFinancials12.7xn=25Utilities: 12.1x median across 58 dealsUtilities12.1xn=58Consumer & Retail: 10.3x median across 141 dealsConsumer & Retail10.3xn=141Materials: 9.6x median across 40 dealsMaterials9.6xn=40Other: 9.5x median across 31 dealsOther9.5xn=31Media & Telecom: 9.3x median across 41 dealsMedia & Telecom9.3xn=41Energy: 8.5x median across 34 dealsEnergy8.5xn=34
Deals by sector
Technology: 509 dealsTechnology509Financials: 504 dealsFinancials504Healthcare: 437 dealsHealthcare437Industrials: 304 dealsIndustrials304Consumer & Retail: 303 dealsConsumer & Retail303Real Estate: 234 dealsReal Estate234Business Services: 198 dealsBusiness Services198Energy: 171 dealsEnergy171Media & Telecom: 144 dealsMedia & Telecom144Utilities: 119 dealsUtilities119Materials: 109 dealsMaterials109Other: 106 dealsOther106
Deals by buyer type
Financial sponsor: 18 dealsFinancial sponsor18Strategic: 256 dealsStrategic256Management / founder: 1 dealsManagement / founder1Controlling holder: 2 dealsControlling holder2Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 160 dealsUnclassified160
Deals by enterprise value
Under $250m: 178 dealsUnder $250m178$250m to $1bn: 85 deals$250m to $1bn85$1bn to $5bn: 103 deals$1bn to $5bn103$5bn to $20bn: 61 deals$5bn to $20bn61Over $20bn: 9 dealsOver $20bn9Not computed: 1 dealsNot computed1
Deals by industry code
Chemicals, Pharmaceuticals & Allied Products: 252 dealsChemicals, Pharmaceutic…252Instruments, Medical Devices & Optical Goods: 101 dealsInstruments, Medical De…101Health Services: 84 dealsHealth Services84
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
DMK PHARMACEUTICALS Corp
2023-02-24 · Public merger · $0.13 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$18mn.a.3.7x
n.a.
DEFM14A
Includes stock
Cardiovascular Systems Inc
2023-02-08 · Public merger · $20.00 a share
Abbott Laboratories
Strategic
Healthcare$707mn.a.3.0x
50%
44% to VWAP
DEFM14A
All cash
Oak Street Health, Inc.
2023-02-07 · Public merger · $39.00 a share
CVS Pharmacy, Inc.
Strategic
Healthcare$10bnn.a.4.6x
n.a.
DEFM14A
All cash
AlerisLife Inc.
2023-02-02 · Take-private · $1.98 a share
Abp Acquisition 2 LLC
Management / founder
Healthcare$42mn.a.0.1x
n.a.
SC 13E3
All cash
Horizon Therapeutics Public Ltd Co
2023-01-23 (filed) · Public merger · $116.50 a share
Not named in the filing
Unclassified
Healthcare$27bn26.4x7.3x
49%
DEFM14A
All cash
Apollo Endosurgery, Inc.
2022-11-29 · Public merger · $10.00 a share
Boston Scientific
Strategic
Healthcare$383mn.a.5.3x
67%
DEFM14A
All cash
CalciMedica, Inc.
2022-11-21 · Public merger · $0.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Inc.
Strategic
Healthcare-$33mn.a.n.a.
n.a.
DEFM14A
Includes stock
Opiant Pharmaceuticals, Inc.
2022-11-13 · Public merger · $20.00 a share
Indivior Inc.
Strategic
Healthcare$80mn.a.3.6x
111%
DEFM14A
All cash
Renovacor, Inc.
2022-10-31 (filed) · Public merger · $9.99 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Rocket’s Merger Subs
Unclassified
Healthcare$107mn.a.n.a.
n.a.
DEFM14A
Includes stock
Myovant Sciences Ltd.
2022-10-23 · Take-private · $27.00 a share
Board book on file →
Sumitomo Pharma Co., LTD.
Strategic
Healthcare$2.2bnn.a.6.7x
50%
48% to VWAP
SC 13E3
All cash
Old Ayala, Inc
2022-10-18 · Public merger · $4.75 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Advaxis, Inc.
Strategic
Healthcare$59mn.a.34.6x
n.a.
DEFM14A
Includes stock
Aveo Pharmaceuticals, Inc.
2022-10-18 · Public merger · $15.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$442mn.a.4.7x
43%
DEFM14A
Includes stock
EUDA Health Holdings Ltd
2022-10-13 (filed) · Public merger · $10.00 a share
Not named in the filing
Unclassified
Healthcare$111mn.a.10.5x
n.a.
DEFM14A
All cash
SeaSpine Holdings Corp
2022-10-10 · Public merger · $7.64 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Orthofix Medical Inc.
Strategic
Healthcare$237mn.a.1.0x
n.a.
DEFM14A
Includes stock
Coeptis Therapeutics Inc.
2022-09-30 (filed) · Public merger · $10.00 a share
Bull Horn Holdings Corp.
Strategic
Healthcare$383mn.a.n.a.
n.a.
DEFM14A
All cash
Signify Health, Inc.
2022-09-02 · Public merger · $30.50 a share
CVS Pharmacy, Inc.
Strategic
Healthcare$5.3bnn.a.6.3x
n.a.
DEFM14A
All cash
Aerie Pharmaceuticals Inc
2022-08-22 · Public merger · $15.25 a share
Alcon Research, LLC
Strategic
Healthcare$568mn.a.2.7x
39%
DEFM14A
All cash
Global Blood Therapeutics, Inc.
2022-08-07 · Public merger · $68.50 a share
Pfizer Inc.
Strategic
Healthcare$4.4bnn.a.18.5x
102%
110% to VWAP
DEFM14A
All cash
ChemoCentryx, Inc.
2022-08-03 · Public merger · $52.00 a share
Held out of the multiples: EV / LTM revenue 91.3x above 60x
Not named in the filing
Unclassified
Healthcare$3.4bnn.a.91.3x
116%
DEFM14A
All cash
Stealth BioTherapeutics Corp
2022-07-31 · Take-private · $0.38 a share
Board book on file →
Equal Talent Investments LTD
Financial sponsor
Healthcare$234mn.a.n.a.
34%
SC 13E3
All cash
Hanger, Inc.
2022-07-21 · Public merger · $18.75 a share
Hero Parent, Inc.
Unclassified
Healthcare$1.2bn11.7x1.0x
26%
29% to VWAP
DEFM14A
All cash
1Life Healthcare Inc
2022-07-20 · Public merger · $18.00 a share
Amazon.com, Inc.
Strategic
Healthcare$3.1bnn.a.3.5x
83%
DEFM14A
All cash
Meridian Bioscience Inc
2022-07-07 · Public merger · $34.00 a share
Not named in the filing
Unclassified
Healthcare$1.4bn21.9x4.1x
9%
DEFM14A
All cash
Tyme Technologies, Inc.
2022-07-03 · Public merger · $2.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Syros Pharmaceuticals, Inc.
Strategic
Healthcare$353mn.a.n.a.
n.a.
DEFM14A
Includes stock
Convey Health Solutions Holdings, Inc.
2022-06-20 · Take-private · $10.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Board book on file →
TPG HC Cannes Holdings, L.P.
Financial sponsor
Healthcare$1.0bn24.5x2.9x
143%
99% to VWAP
SC 13E3
Includes stock

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More